55 results about "Glycemic" patented technology

This invention provides a low glycemic index blueberry extract and its preparation method, belonging to the field of beverage processing technology. The preparation method includes the following steps: blueberries are pulped, then fermented using a compound strain of Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium, filtered through a membrane filtration device to obtain a blueberry fermentation broth; blueberries are crushed, the pH of an ethanol solution is adjusted to 2-3 with citric acid, followed by ultrasonic extraction, centrifugation to collect the supernatant, and then vacuum distillation of the supernatant to obtain anthocyanin extract concentrate; the anthocyanin extract concentrate is freeze-dried to obtain anthocyanin extract dried product; the anthocyanin extract dried product and blueberry fermentation broth are mixed evenly at a mass-volume ratio of (0.2-0.3) g:1L, then maltitol is added to adjust acidity and sweetness, homogenized, filtered, and sterilized to obtain the blueberry extract. By using compound probiotic fermentation to reduce sugar content and combining it with alcohol extraction to enhance anthocyanins and improve efficacy, the resulting product has anthocyanin content ≥400 mg / L and a low GI.

This invention discloses a low-allergen compound oral liquid for middle-aged and elderly people that protects the liver, stabilizes blood pressure, blood sugar, and blood lipids, combats aging, aids sleep, and prevents Alzheimer's disease. It belongs to the field of food and medicine homology health food technology. The invention uses kudzu root extract, Japanese raisin tree fruit extract, mulberry leaf extract, jujube seed saponins, Acer truncatum seed oil (nervonic acid), blueberry anthocyanins, bitter melon small molecule peptides, wolfberry polysaccharides, γ-aminobutyric acid, and chrysanthemum flavonoids as core active ingredients, refined with a prebiotic system. This invention achieves comprehensive conditioning effects for middle-aged and elderly people through the synergistic action of five pathways: liver protection and metabolism, vascular regulation, anti-oxidation and anti-aging, nerve calming, and brain nerve repair. It simultaneously nourishes and protects the liver, stabilizes blood pressure, blood sugar, and blood lipids, delays aging, improves intractable insomnia, enhances memory, slows brain atrophy, and prevents Alzheimer's disease. This formula strictly avoids eight common allergens, is pure and mild, and contains no irritating additives, making it suitable for long-term use by middle-aged and elderly people with weak constitutions. This product is an oral liquid formulation, with small molecule extraction, strong permeability, rapid absorption, low gastrointestinal burden, stable production process, and high safety. It has extremely high clinical promotion value and industrialization prospects.

An insulin delivery system for diabetes management includes a patch-based insulin pump configured to deliver insulin to a user, a user input button disposed on the patch-based insulin pump, a processor configured to execute a hybrid closed loop algorithm that automatically controls insulin delivery based on glucose levels. The user input button is configured to receive user input comprising a sequence of button presses that communicate contextual information about user activities to the hybrid closed loop algorithm, the contextual information being distinct from direct insulin bolus delivery commands. The contextual information may include meal intake, physical activity, and sleep status communicated through different sequences of button presses. The system includes confirmation mechanisms that provide feedback and allow cancellation of inputs, enabling discrete real-time communication of personalized data to enhance diabetes management.

Systems and methods are provided for reconciling untrusted data of a subject using trusted data pertaining to the subject. Systems and methods are directed to evaluating differences in predicted data with respect to corresponding received data. Systems and methods estimate metabolic states from a combination of trusted and untrusted metabolic inputs, along with optionally using a personalized mathematical model with parameter optimization. Systems and methods provide for reconciled untrusted inputs with their measured impact of the glycemic signals that is consistent with a metabolic model. Estimation of future metabolic states for decision support and automated insulin dosing is enabled. Replay of scenarios with estimated or reconciled data is also provided.

The application discloses a quinoa hexapeptide with a blood sugar lowering effect and application thereof, and belongs to the technical field of bioactive peptides. The amino acid sequence of the quinoa hexapeptide PGSPGR is Pro-Gly-Ser-Pro-Gly-Arg. The quinoa hexapeptide PGSPGR has alpha-glucosidase inhibitory activity and can effectively reduce blood sugar level, and therefore, can be applied to preparation of medicines or food for lowering blood sugar. The application further provides a polypeptide containing the peptide segment PGSPGR and a quinoa peptide rich in the polypeptide, and the polypeptide and the quinoa peptide are applied to preparation of medicines or food for lowering blood sugar, thereby providing a new scheme and theoretical basis for treatment of diabetes, and having good market prospect and application potential.

This invention provides a mulberry leaf and wolfberry composition, comprising aqueous extracts of wolfberry, mulberry leaves, astragalus, yam, kudzu root, and green tea. This invention also provides oral preparations and food products containing this composition. Furthermore, this invention provides the application of the composition or oral preparation in the preparation of health foods that help maintain healthy blood sugar levels and hypoglycemic drugs. The composition provided by this invention has the effect of lowering blood sugar, and the selected raw materials are highly safe, have few toxic side effects, and are widely available, possessing significant market value and development prospects.

Provided are methods for treating glucose-related metabolic disorders in a subject. In some aspects, the methods comprise enterally administering an effective amount of a beta-glucan oligosaccharide prior to and / or during the subject consuming a glucose source.

Orally administered pharmaceutical compositions comprising incretin or its analogues or derivatives are presented, which allow for prolonged glycemic control. The formulations presented herein incorporate a self-emulsifying drug delivery system (SEDDS). Advantageously, such formulations provide protection in the upper gastrointestinal tract from proteolytic conditions while allowing for efficient drug release and absorption in the lower gastrointestinal tract.

Systems and methods are disclosed that employ several or numerous factors in the determination of a glycemic urgency index (GUI), which may be based on a measured blood glucose level as well as other factors. The other factors may include time derivatives of the glucose level and / or other factors, e.g., user - entered data, data measured by other sensors or received from a network source, or historical data. The GUI is then presented to the user in an interesting way, e.g., via a background color or other inconspicuous notifier, e.g., on a mobile device such as a smart phone. The GUI may also be employed in the triggering of actionable alerts and alarms on an electronic device for the user. The GUI, or another index calculated from combinations of the variables and parameters described, may further be employed to drive a medicament delivery device such as a pump. 20 24 21 64 74 30 A ug 2 02 4 2 0 2 4 2 1 6 4 7 4 3 0 2 0 2 4 A u g

The present disclosure describes an analyte monitoring system that tracks a host's glycemic control levels over time to determine disease progression. The analyte monitoring system may then administer a treatment to address the disease progression.

This invention relates to animal-derived lactic acid bacteria with lipid-lowering and blood sugar-lowering functions. Specifically, it provides a lactic acid bacterium that has high safety, plays an important role in regulating the balance of the human intestinal microecology, and has lipid-lowering and blood sugar-lowering effects. This lactic acid bacterium is named *L. reuteri* 4434-2aT, strain number 4434-2aT, and was deposited on January 20, 2026, at the Guangdong Provincial Center for Microbial Culture Collection (GDMCC), located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC NO: 67711.

The application discloses a kind of for anti-aging regulation blood fat blood sugar, the purification method of high-purity tea pigment of uric acid.It is with summer and autumn tea crude leaf, tea residue as raw material, by enzyme directed conversion, double-frequency ultrasonic subcritical water extraction, three-stage membrane separation, molecularly imprinted resin precision purification, the integrated innovative process of low-temperature freeze drying, prepare high-purity tea pigment with total purity ≥95%, the flavan-3-ols ≥35%, active retention rate ≥95%, realize the safety standard of no solvent residue, low caffeine, desalination and heavy metal removal.The high-purity tea pigment has four synergistic effects of strong antioxidant anti-aging, protecting blood vessels and improving circulation, regulating blood sugar, inhibiting uric acid generation and promoting excretion, and can be widely applied to functional food, health food, pharmaceutical intermediates and special medical food.The application has advanced process, green environmental protection, high raw material utilization rate and batch stability, solves the technical bottleneck of low purity, poor activity and insufficient safety of traditional tea pigment, and has significant innovation, practicality and industrialization value.

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

Methods and apparatus, including computer program products, are provided for processing analyte data. In some exemplary embodiments, there is provided a method. The method may include selecting at least one module from among a plurality of modules, the selection performed based on metadata including one or more of the following rules: whether the at least one module can be used with a type of device, whether the at least one module can be used with a glycemic state of a host, and whether the at least one module can be used with an expected volume of data generated by the type of device; and generating a report including the selected at least one module configured to present information representative of the glucose concentration level measured in the host. Related systems, methods, and articles of manufacture are also disclosed.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

A microparticle of bitter melon extract with blood sugar-regulating properties, comprising a microparticle body that is a solid spherical structure formed by granulation of an effective amount of bitter melon extract uniformly mixed with a pharmaceutically acceptable binder; wherein the bitter melon extract comprises at least charantin, momordicin and momordica peptides and wherein the structure of the particle body is designed to ensure good flowability and uniform, controlled release of the active ingredients in the gastrointestinal tract.

This invention relates to a *Malus toringo* exosome-like nanoparticle, its preparation method, and its uses, belonging to the pharmaceutical field. The *Malus toringo* exosome-like nanoparticles of this invention are derived from the plant *Malus toringo*, belonging to the Rosaceae family. Malus toringoides (Rehd.) Hughes and Begonia variegated Malus transitoria Using fresh leaves of *Batal.* Schneid. as raw material, exosome-like nanoparticles were extracted from *Batal.* Schneid. using differential centrifugation and ultra-high speed centrifugation. The *Batal.* Schneid. exosome-like nanoparticles of this invention exhibit significant hypoglycemic and lipid-regulating effects, significantly reducing fasting blood glucose, improving glucose tolerance, increasing insulin sensitivity, and lowering serum TC and TG levels; they also improve liver pathological damage, significantly reducing hepatic lipid accumulation and steatosis, with effects superior to rosiglitazone; while lowering blood glucose and regulating lipids, the *Batal.* Schneid. exosome-like nanoparticles of this invention also inhibit weight gain without the risk of liver damage, demonstrating good comprehensive therapeutic potential.

The application discloses a kind of low-glycemic food processing technology of fusion white kidney bean extract, it is related to food processing technical field, including the following steps: raw material pretreatment: starch raw material is pulverized and handled, obtain starch powder, the starch powder is sequentially treated with modification, gelatinization, modification, and obtain modified starch base, the modification is used to increase resistant starch content in starch powder, reduce fast-digesting starch content;Add white kidney bean extract: white kidney bean extract is microencapsulated and coated with pretreatment, and obtain coated white kidney bean extract;The coated white kidney bean extract is added to modified starch base, and after being mixed uniformly, obtain mixed base;Forming and curing: the mixed base is formed and cured.The low-glycemic food processing technology of fusion white kidney bean extract, product GI value is low, white kidney bean extract activity retention rate is high, resistant starch content is effectively improved, while ensuring product taste and boiling resistance.

This invention discloses the application of modified chestnut starch in the preparation of hypoglycemic functional foods and a low-GI modified chestnut starch recombinant rice and its preparation method, relating to the fields of food processing and functional food technology. The modified chestnut starch contains no less than 40% resistant starch; the hypoglycemic functional foods are staple foods, supplementary foods, or dietary supplements for people with type 2 diabetes. The modified chestnut starch exerts a multi-target hypoglycemic effect, not only lowering fasting blood glucose and improving glucose tolerance, but also simultaneously regulating lipid metabolism and reducing liver inflammation and damage. The prepared recombinant rice has a GI value as low as 48.25, while also possessing good edible quality. This solves the technical pain point of existing low-GI recombinant rice, which suffers from "high functionality but low edible quality," achieving a synergistic improvement in hypoglycemic functionality and edible quality. The process is simple, parameters are controllable, and production costs are low, making it suitable for large-scale industrial production and with broad market prospects.

Systems and methods for improved continuous glucose monitoring ("CGM") are provided. The disclosed systems and methods provide for tracking of analyte measurements, CGM-related event data, and sensor-related data. Aspects of the present disclosure allow one or more users' data and analyte measurements to be displayed in a graphical user interface for improved functionality. The graphical user interface includes a history graph of analyte measurements and incorporates event data representing a plurality of event indications. The time frame of the history graph is adjustable by the user, and events can be presented as groups within the event indication based on the time frame of the history graph. The graphical user interface may also be configured to display a graph of trend data for each individual event, and a sensor life indication representing the time remaining until expiration of one or more analyte sensors.

A glucose data analysis system includes an on-body unit and a processor. The on-body unit is configured to measure glucose levels of a user. The processor is configured to receive therapy data of the user including glucose data monitored by the on-body unit, analyze daily glucose profiles of the glucose data over an analysis period by a machine learning model, group the daily glucose profiles into two or more patterns based on the analysis performed by the machine learning model, and output a report including identification of the two or more patterns associated with each daily glucose profile. Advantageously the system may identify and visualize patterns of glucose data, identify recurring patterns, identify correlations between patterns and external events (e.g., medication, meals, exercise, sleep, stress, etc.), reduce glycemic variability, streamline analysis with unsupervised machine learning (e.g., no training), and provide recommendations for user intervention or actions based on identified patterns.

An implantable glucose sensor includes: a housing, two injecting electrodes for injecting current into the tissue, two sensing electrodes for measuring impedance in the tissue, a coil within the housing for powering the sensor via a power source, a circuit board within the housing, the circuit board being electrically connected to the two sensing electrodes and the two injecting electrodes and the coil, and a communication unit for communicating data. The communication unit is connected to the circuit board. The two sensing electrodes and the two injecting electrodes are arranged on an outer surface of a first part of the housing. The outer surface of first part is of a convex shape. The two sensing electrodes and the two injecting electrodes are embedded in the convex shape so that they are flush with the outer surface of the convex shape.

Glucose level measurements of a user are obtained over time, such as from a wearable glucose monitoring device being worn by the user. These glucose level measurements can be produced substantially continuously, such that the device may be configured to produce the glucose level measurements at regular or irregular intervals of time, responsive to establishing a communicative coupling with a different device, and so forth. These glucose level measurements are analyzed to detect deviations from past glucose measurements, such as glucose measurements received earlier in the day or glucose measurements received at corresponding times of one or more preceding days. Indications of detected deviations are provided to the user or communicated elsewhere, such as to a healthcare professional.

This invention relates to the field of food processing technology and discloses a meal replacement powder composition with hypoglycemic activity and its preparation method. The meal replacement powder uses buckwheat flour, yam flour, bitter melon flour, konjac oligosaccharide, polygonatum powder, and hawthorn powder as raw materials, with an optimized ratio of 2.00g buckwheat flour, 1.00g yam flour, 0.50g bitter melon flour, 0.40g konjac oligosaccharide, 0.40g polygonatum powder, and 0.45g hawthorn powder. The preparation method includes raw material pretreatment and precise ingredient mixing steps. The meal replacement powder of this invention is rich in total polysaccharides, total flavonoids, and total phenolic active ingredients. Its in vitro α-glucosidase inhibition rate is similar to that of acarbose, and its α-amylase inhibition rate is superior to that of acarbose. With a GI value of 53.92 (low GI food), it can effectively delay the rise in postprandial blood glucose, meeting the blood sugar control needs of people with prediabetes. The process is simple, the raw materials are natural, and it has the potential for large-scale industrialization.

A fermented, food-grade, slow-glycemic staple food flour composition, its preparation method, and its application include the following raw materials in weight percentages: 200-300 parts selenium-enriched flour and the following food-grade, medicinal ingredients: 25-35 parts yam, 25-35 parts coix seed, 20-30 parts white hyacinth bean, 20-30 parts red adzuki bean, 15-25 parts kudzu root, 20-30 parts astragalus, 5-10 parts honeysuckle, 15-25 parts monk fruit, 15-25 parts mulberry leaf, 5-10 parts wolfberry, 20-30 parts platycodon, 20-30 parts polygonatum, 20-30 parts poria cocos, 15-25 parts red date, and 20-30 parts hawthorn; it also includes compound enzymatic hydrolysis and compound probiotics. This invention can stabilize postprandial blood sugar and has both nutritional fortification and intestinal regulation functions.